TSX:7203.T News 18 January 2026

January 23, 2026, 1:21 PM EST. Johnson & Johnson (JNJ) and Merck (MRK) stand out as durable picks for long-term investors, driven by strong healthcare franchises. Merck's oncology focus, led by its blockbuster cancer drug Keytruda, positions it for continued sales growth despite looming patent expiration in 2028. The company also expands with new approvals and formulations to sustain momentum. Johnson & Johnson benefits from a diversified portfolio across pharmaceuticals and medical devices, consistently delivering revenue and earnings, even amid challenges. Both stocks offer attractive dividend yields - Merck at 3.1% with nearly doubling payouts historically, and Johnson & Johnson at 2.35%. Their scale, innovation, and dividend track records make them solid candidates for wealth accumulation over two decades, despite short-term volatility.